Developing AFFIRM assays for detection of potential biomarkers for relapsed breast cancer in plasma
Today, breast cancer is the leading cause of cancer related death in women. Early detection of breast cancer relapse presents increased treatment options and better control. Protein biomarkers from plasma are currently measured by state-of-the-art methods like ELISA, which require antibodies with high sensitivity and specificity. Developing such assays is laborious and time consuming. Thus, there
